Senior Accountant

At least 5 years of related experience and/or training with 1-2 years of biotechnology or life science industry experience required.

Working knowledge of all aspects of accounting and financial reporting.

As the Senior Accountant you will have a direct impact on accounting and reporting activities for a fast-growing, public biotech.

Reporting to the Director, Accounting, you will be responsible for (i) assisting with monthly and quarterly close activities such as preparation of journal entries, reconciliations, financial analyses, supporting documentation and financial statements, (ii) assisting with systems implementations, including potential new ERP, (iii) assisting with management and execution of our independent audit and Sarbanes-Oxley activities, and (iv) supporting other activities such as clinical trial accruals and collaboration arrangements.

You must have experience working with public biopharma companies and/or public accounting experience to be successful in this role.

This is an exciting opportunity to assist with the continued build-out of the accounting and financial reporting processes and have a significant impact on the future success of the company. We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives.

Complete monthly and quarterly account reconciliations to ensure accurate reporting and ledger maintenance including but not limited to cash, accounts receivable, accounts payable, general ledger, fixed assets, payroll, prepaids, and purchasing.

Assists with the Sarbanes-Oxley activities including updating system documentation, testing controls, remediating control deficiencies and coordination efforts with the auditors.

We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit

www.dianthustx.com

and follow us on

LinkedIn

.